Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Regulatory News:Sensorion (FR001401A9Z0 — ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announ…